Editor-in-Chief, Deputy Editor 2017-2019

 

Editor-in-Chief:

Tom MOREELS

 

Deputy Editor:

Nicolas LANTHIER

 

Symposium

    Display #  

Results 1 - 20 of 27


An overview on a novel adjuvanted prophylactic hepatitis B vaccine


Price: €10,00

No abstract available. [Product Details...]



Development of novel anti-HCV therapies : HCV protease, helicase, and polymerase as therapeutic targets


Price: €10,00

No abstract available. [Product Details...]



Editorial introduction


Price: €10,00

Viral hepatitis is a major public health problem world-wide. It has been estimated that more than 300 million people are suffering from this infectious disease with a significant morbidity and mortality rate. In the last decade, there have been tremendous progresses in the discoveries, understanding of disease pathogenesis, diagnostic, prevention and the treatment of... [Product Details...]



Epidemiology of hepatocellular carcinoma and its viral risk factors


Price: €10,00

No abstract available. [Product Details...]



HCV, HDV and autoimmunity


Price: €10,00

No abstract available. [Product Details...]



HCV-infection and hepatocellular carcinoma


Price: €10,00

No abstract available. [Product Details...]



Hepatic chemoembolization : clinical and experimental correlation


Price: €10,00

Chemoembolization has become the preferred treatment for patients with inoperable, hypervascular hepatic malignancies in the Far East, but controversial elsewhere. In vivo microscopy in addition to other experimental procedures are used in this presentation to better understand the mechanisms involved in chemoembolization. In chemoembolization Lipiodol acts as a contrast material, a vehicle for chemotherapy and an embolic agent. Although not optimal, Lipiodol injected into the hepatic artery, traverses the peribiliary plexus to the portal veins resulting in a dual embolization. Chemoembolization creates ischemia, slows arterial flow and increases the contact time between the infusate and the neoplasms, increasing the tumor cell kill. However, the vascular occlusion also produces infarction and fibrosis compounding the already existing cirrhosis frequently associated with hepatocellular carcinoma. Lipiodol/ethanol (3:1) injected into the segmental or lobar hepatic artery supplying the neoplasm also gains access to the associated portal venous branches causing focal ablation. This preoperative approach is easier to perform than direct portal vein occlusion, with less parenchymal damage and comparable hypertrophy of the remnant liver frequently necessary for adequate hepatic function following resection. Polymer-drug conjugates, e.g. PG-TXL, have considerable potential for intra-arterial delivery especially with the dramatic increase in concentration of the drug in the tumor and its efficacy. Using in vivo microscopy especially with green fluorescent protein (GFP) gene as an efficient and non-toxic tumor cell marker, the events leading to hepatic metastases can be documented which will serve to better evaluate these varied techniques of chemoembolization. [Product Details...]



Hepatitis B virus and liver transplantation


Price: €10,00

No abstract available. [Product Details...]



Hepatitis B virus receptor : the role of human annexin V


Price: €10,00

No abstract available. [Product Details...]



Hepatitis C : virology, clinical aspects and the relation to cryoglobulinemia


Price: €10,00

No abstract available. [Product Details...]



Hepatitis C virus and transplantation


Price: €10,00

No abstract available. [Product Details...]



Hepatitis D : virology, clinical and epidemiological aspects


Price: €10,00

No abstract available. [Product Details...]



Immune therapy of hepatitis B virus (HBV) chronic infection. European experience


Price: €10,00

No abstract available. [Product Details...]



Improvement of chronic active hepatitis C in chronically infected chimpanzees after therapeutic vaccination with the HCV E1 protein


Price: €10,00

No abstract available. [Product Details...]



In vitro assays for drug testing : continuous cell lines


Price: €10,00

No abstract available. [Product Details...]



Infectious synthetic HCV transcripts


Price: €10,00

No abstract available. [Product Details...]



New agent to cause acute fulminant hepatitis ?


Price: €10,00

No abstract available. [Product Details...]



New nucleoside analogues for chronic hepatitis B


Price: €10,00

No abstract available. [Product Details...]



Non-surgical treatment of hepatocellular carcinoma (HCC)


Price: €10,00

No abstract available. [Product Details...]



Percutaneous treatment of liver metastases


Price: €10,00

Hepatic resection is the mainstay in the curative... [Product Details...]




Display #  
Results 1 - 20 of 27